Please enable Javascript
Conferences
Partners
Expert Interviews
Atherosclerotic Disease
Atrial Fibrillation
Heart Failure
Hypertension
Interventional Care
Lipid Managment
Preventive Care
Menu
left ventricular mass
EMPA-HEART: Empagliflozin Reversed LV Remodeling in T2D Patients
DocWire News Editors
AHA Scientific Sessions 2018
|
April 11, 2023
Empagliflozin, an SGLT2 inhibitor, significantly reversed left ventricular (LV) remodeling in a population of diabetic ...
Read More